Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Marchetti M. et al, (2023), Ther Adv Hematol, 14
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.
Zhang X-Y. and Collins GP., (2022), Curr Oncol Rep, 24, 1477 - 1488
HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).
Carlo-Stella C. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A. et al, (2022), Br J Haematol, 198, 492 - 502
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA. et al, (2022), Circ Heart Fail, 15
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
Follows GA. et al, (2022), Br J Haematol, 197, 558 - 572
Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
Vadgama S. et al, (2022), Value Health, 25, 1010 - 1017
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.
Lim SH. et al, (2022), Nat Cancer, 3, 552 - 564
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
Fox CP. et al, (2022), Br J Haematol, 196, 507 - 522
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
Booth S. et al, (2022), Br J Haematol, 196, 892 - 901
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19.
Várnai C. et al, (2022), JAMA Netw Open, 5
A Review of the Prevention of Mother-to-Child Transmission of Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1) With a Proposed Management Algorithm.
Barr RS. et al, (2022), Front Med (Lausanne), 9
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA).
Infante MS. et al, (2022), Front Oncol, 12
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins GP. et al, (2021), Leuk Lymphoma, 62, 2625 - 2636
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
Collins GP. et al, (2021), Hemasphere, 5
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M. et al, (2021), J Hematol Oncol, 14
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox CP. et al, (2021), Blood Adv, 5, 4073 - 4082
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
Pagano L. et al, (2021), J Hematol Oncol, 14
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Herrera AF. et al, (2021), Blood Adv, 5, 3387 - 3396